AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7012968 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent tetracycline therapy
Number of subjects: 2
Study 7012968 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2
Study 31944884 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium nitride (TIN) Gracey curette
Number of subjects: 20
Study 31944884 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (Er:YAG tip) chisel
Number of subjects: 20
Study 31944884 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic piezoelectric device with a special tip designed for root surfaces (H3)
Number of subjects: 20
Study 31944884 — intervention group
Group type: EXPERIMENTAL
Intervention: Stainless steel (SS) Gracey curette
Number of subjects: 20
Study 30632208 — intervention group
Group type: EXPERIMENTAL
Intervention: Dornase alfa (2.5 ml, nebulized once daily for 1 month)
Number of subjects: 32
Study 30632208 — intervention group
Group type: COMPARATOR
Intervention: Control (5 ml of isotonic saline, nebulized once daily for 1 month)
Number of subjects: 32
Study 30632208 — intervention group
Group type: EXPERIMENTAL
Intervention: Dornase alfa
Number of subjects: 32
Study 30632208 — intervention group
Group type: COMPARATOR
Intervention: Control (isotonic saline)
Number of subjects: 32
Study 28291691 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured educational intervention applied to experimental group once a month for three months.
Number of subjects: 103
Study 26390397 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking under single task (walk only) condition
Number of subjects: 38
Study 26390397 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking under dual task (walk performing a simultaneous cognitive task) condition
Number of subjects: 38
Study 26390397 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive performance during treadmill walking
Number of subjects: 38
Study 26390397 — intervention group
Group type: COMPARATOR
Intervention: Overground walking under single task condition
Number of subjects: 38
Study 26390397 — intervention group
Group type: COMPARATOR
Intervention: Overground walking under dual task condition
Number of subjects: 38
Study 24290960 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma c‐proteasome activity measured at 12‐16 h after injury
Number of subjects: 50
Study 24290960 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma c‐proteasome activity
Number of subjects: 50
Study 22658931 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthrax Vaccine Adsorbed (AVA)
Number of subjects: 726
Study 19172441 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual fundal pressure during the second stage of labor
Number of subjects: 197
Study 19172441 — intervention group
Group type: COMPARATOR
Intervention: No manual fundal pressure during the second stage of labor
Number of subjects: 197
Study 17222288 — intervention group
Group type: EXPERIMENTAL
Intervention: De‐nicotinized cigarettes
Number of subjects: 30
Study 17222288 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine‐containing cigarettes
Number of subjects: 30
Study 17222288 — intervention group
Group type: COMPARATOR
Intervention: No smoking
Number of subjects: 30
Study 15177816 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological awareness, morphological/syntactic skill, and naming speed
Number of subjects: 199
Study 15177816 — intervention group
Group type: EXPERIMENTAL
Intervention: Naming speed
Number of subjects: 199
Study 11988933 — intervention group
Group type: EXPERIMENTAL
Intervention: Type I collagen (filled defects)
Number of subjects: 16
Study 11988933 — intervention group
Group type: EXPERIMENTAL
Intervention: Type I collagen (filled defects in patients)
Number of subjects: 16
Study 11988933 — intervention group
Group type: COMPARATOR
Intervention: Control (unfilled defects in rabbits)
Number of subjects: 16
Study 11988933 — intervention group
Group type: COMPARATOR
Intervention: Control (unfilled cavities in patients)
Number of subjects: 16
Study 9579258 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tenoxicam (20 mg) administered 30 min before surgery
Number of subjects: 77
Study 9579258 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tenoxicam (20 mg) administered after incision
Number of subjects: 77
Study 7622092 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategies (press releases and newspaper advertisements)
Number of subjects: 0
Study 7622092 — intervention group
Group type: COMPARATOR
Intervention: Declined participants
Number of subjects: 0
Study 2793304 — intervention group
Group type: EXPERIMENTAL
Intervention: Cambridge Diet (CD)
Number of subjects: 17
Study 2793304 — intervention group
Group type: COMPARATOR
Intervention: Milk diet
Number of subjects: 17
Study 2793304 — intervention group
Group type: EXPERIMENTAL
Intervention: Change from CD to Milk
Number of subjects: 17
Study 2793304 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw wiring (during outpatient phase)
Number of subjects: 17
Study 6108726 — intervention group
Group type: EXPERIMENTAL
Intervention: KWD 2131
Number of subjects: 12
Study 6108726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30926451 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-learning training
Number of subjects: 1301
Study 30926451 — intervention group
Group type: COMPARATOR
Intervention: Instructor-led training
Number of subjects: 1301
Study 28219610 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir plus emtricitabine and tenofovir alafenamide
Number of subjects: 98
Study 28219610 — intervention group
Group type: COMPARATOR
Intervention: Dolutegravir plus emtricitabine and tenofovir alafenamide
Number of subjects: 98
Study 25845544 — intervention group
Group type: EXPERIMENTAL
Intervention: Next generation KA01 chitosan wound dressing
Number of subjects: 90
Study 25845544 — intervention group
Group type: COMPARATOR
Intervention: Traditional vaseline gauze
Number of subjects: 90
Study 23289969 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg/day)
Number of subjects: 46
Study 23289969 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (80-320 mg/day)
Number of subjects: 46
Study 19341012 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored psychosocial intervention
Number of subjects: 28
Study 19341012 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 28
Study 15468367 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac solution (50 drops applied 3 times daily for 12 weeks)
Number of subjects: 622
Study 15468367 — intervention group
Group type: COMPARATOR
Intervention: Oral diclofenac (50 mg capsules taken 3 times daily for 12 weeks)
Number of subjects: 622
Study 11020769 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid drainage during surgery
Number of subjects: 0
Study 11020769 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical procedure without cerebrospinal fluid drainage
Number of subjects: 0
Study 8642490 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat/soy cereals with 8.0% dietary fiber (DF)
Number of subjects: 57
Study 8642490 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat/soy cereals with 1.8% dietary fiber (DF)
Number of subjects: 57
Study 8642490 — intervention group
Group type: COMPARATOR
Intervention: Wheat/milk cereals
Number of subjects: 57
Study 1557274 — intervention group
Group type: EXPERIMENTAL
Intervention: Capitation payments with financial risk-sharing
Number of subjects: 0
Study 1557274 — intervention group
Group type: COMPARATOR
Intervention: Visit fees set at twice regular Medicaid fees
Number of subjects: 0
Study 1557274 — intervention group
Group type: COMPARATOR
Intervention: Regular Medicaid program (fee-for-service, low fees)
Number of subjects: 0
Study 3926613 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg isosorbide dinitrate (ISDN) in sustained-release form (SR)
Number of subjects: 15
Study 3926613 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg ISDN SR with 100 mg atenolol
Number of subjects: 15
Study 3926613 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg ISDN SR, 100 mg atenolol and 20 mg nifedipine in sustained release form
Number of subjects: 15
Study 3926613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31669615 — intervention group
Group type: EXPERIMENTAL
Intervention: Endplate defects
Number of subjects: 478
Study 31669615 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal and erosive endplate defects
Number of subjects: 478
Study 31669615 — intervention group
Group type: EXPERIMENTAL
Intervention: All three types of endplate defects
Number of subjects: 478
Study 30062603 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexually assertive behavior in women (Study 1a and 1b)
Number of subjects: 1031
Study 30062603 — intervention group
Group type: COMPARATOR
Intervention: Sexually timid behavior in women (Study 1a and 1b)
Number of subjects: 1031
Study 30062603 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexually assertive behavior in men (Study 2)
Number of subjects: 1031
Study 30062603 — intervention group
Group type: COMPARATOR
Intervention: Sexually timid behavior in men (Study 2)
Number of subjects: 1031
Study 28813512 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intervention package of cardiovascular disease care including prescription of a standardized package of medicines, lifestyle intervention advice, and medication adherence advice; implemented over 12 months.
Number of subjects: 28130
Study 28813512 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 28130
Study 28813512 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intervention package of cardiovascular disease care.
Number of subjects: 28130
Study 25332150 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 27
Study 25332150 — intervention group
Group type: COMPARATOR
Intervention: Antiarrhythmic medication
Number of subjects: 27
Study 25332150 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 27
Study 23458201 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 supplementation
Number of subjects: 60
Study 23458201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21131688 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone ring tourniquet (Hemaclear®)
Number of subjects: 20
Study 21131688 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic tourniquet
Number of subjects: 20
Study 19799201 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD) with essential keto/amino acids (0.6 g/kg/day) for 24-48 months
Number of subjects: 46
Study 19799201 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD) with highly purified soya protein (0.3 g/kg/day) in a highly energetic nutrient mixture for 24-48 months
Number of subjects: 46
Study 19799201 — intervention group
Group type: COMPARATOR
Intervention: Free diet
Number of subjects: 46
Study 16473754 — intervention group
Group type: EXPERIMENTAL
Intervention: Real moxibustion
Number of subjects: 71
Study 16473754 — intervention group
Group type: COMPARATOR
Intervention: Sham moxibustion
Number of subjects: 71
Study 16473754 — intervention group
Group type: EXPERIMENTAL
Intervention: Practitioner assessment of treatment (Real moxibustion)
Number of subjects: 71
Study 16473754 — intervention group
Group type: COMPARATOR
Intervention: Practitioner assessment of treatment (Sham moxibustion)
Number of subjects: 71
Study 16473754 — intervention group
Group type: EXPERIMENTAL
Intervention: Practitioner assessment of treatment (Undisclosed treatment)
Number of subjects: 71
Study 15579792 — intervention group
Group type: EXPERIMENTAL
Intervention: l-arginine
Number of subjects: 16
Study 15579792 — intervention group
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Number of subjects: 16
Study 15579792 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH
Number of subjects: 16
Study 15579792 — intervention group
Group type: EXPERIMENTAL
Intervention: GH-releasing peptide (GHRP)-2
Number of subjects: 16
Study 15579792 — intervention group
Group type: EXPERIMENTAL
Intervention: somatostatin-induced rebound
Number of subjects: 16
Study 15579792 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 16
Study 10954887 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleoside analogue reverse transcriptase inhibitors
Number of subjects: 13045
Study 9089057 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 0
Study 9089057 — intervention group
Group type: COMPARATOR
Intervention: Tricyclics (clomipramine and notriptyline)
Number of subjects: 0
Study 9089057 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 0
Study 8470979 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 J of laser energy per application
Number of subjects: 89
Study 8470979 — intervention group
Group type: COMPARATOR
Intervention: 4 J of laser energy per application
Number of subjects: 89
Study 3544187 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose antacid (Maalox 70, 280 mmol/day)
Number of subjects: 171
Study 3544187 — intervention group
Group type: COMPARATOR
Intervention: H2-receptor antagonist cimetidine (Tagamet, 200 mg three times daily and 400 mg/day)
Number of subjects: 171
Study 3544187 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (antacid and cimetidine)
Number of subjects: 171
Study 31094083 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP-B
Number of subjects: 414
Study 31094083 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPOX-B
Number of subjects: 414
Study 31094083 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 414
Study 30355453 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil (35 mg/m2 twice daily on days 1-5 and days 8-12 every 28 days) plus best supportive care
Number of subjects: 507
Study 30355453 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus best supportive care
Number of subjects: 507
Study 27608894 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery
Number of subjects: 240
Study 27608894 — intervention group
Group type: COMPARATOR
Intervention: Traditional resection
Number of subjects: 240
Study 24478326 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OXT) administration
Number of subjects: 0
Study 24478326 — intervention group
Group type: COMPARATOR
Intervention: Control group (subjects without ELS)
Number of subjects: 0
Study 24478326 — intervention group
Group type: COMPARATOR
Intervention: Control group (subjects with ELS)
Number of subjects: 0
Study 23290327 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone for 12 weeks
Number of subjects: 120
Study 23290327 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks followed by ziprasidone for 6 weeks
Number of subjects: 120
Study 23290327 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 120
Study 20979731 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg three times a day for 5±2 days before PCI and a loading dose of 60 mg 30 minutes before PCI, continued for 4 weeks after procedure)
Number of subjects: 101
Study 20979731 — intervention group
Group type: COMPARATOR
Intervention: Control group (similar treatment without trimetazidine)
Number of subjects: 101
Study 18832293 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of tibolone (2.5 mg)
Number of subjects: 24
Study 18832293 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of tibolone (2.5 mg)
Number of subjects: 24
Study 18832293 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol
Number of subjects: 24
Study 16026526 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert ratings of percussion sounds
Number of subjects: 0
Study 16026526 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of ankylosis
Number of subjects: 0
Study 16026526 — intervention group
Group type: COMPARATOR
Intervention: Periotest values (PTV)
Number of subjects: 0
Study 16026526 — intervention group
Group type: COMPARATOR
Intervention: Digital sound wave analysis
Number of subjects: 0
Study 12934402 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilestriol (Group A, n = 21)
Number of subjects: 41
Study 12934402 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group B, n = 20)
Number of subjects: 41
Study 10493474 — intervention group
Group type: EXPERIMENTAL
Intervention: Collective feedback (whole sample)
Number of subjects: 240
Study 10493474 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-only feedback (own professional group only)
Number of subjects: 240
Study 10493474 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed panels (managers and physicians)
Number of subjects: 240
Study 10493474 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-specialty panels (managers or physicians)
Number of subjects: 240
Study 9199117 — intervention group
Group type: EXPERIMENTAL
Intervention: Offspring of hypertensive parents (both mothers and fathers)
Number of subjects: 85
Study 9199117 — intervention group
Group type: COMPARATOR
Intervention: Control group (no family history of hypertension)
Number of subjects: 85
Study 1884611 — intervention group
Group type: COMPARATOR
Intervention: Normoventilation (pH 7.42, PCO2 41 torr)
Number of subjects: 8
Study 1884611 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory alkalosis (pH 7.59, PCO2 27 torr)
Number of subjects: 8
Study 6298047 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial embolization (Embolization group)
Number of subjects: 41
Study 6298047 — intervention group
Group type: COMPARATOR
Intervention: One shot therapy (One shot group)
Number of subjects: 41
Study 30628950 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone bolus (50 mg every 6 hours)
Number of subjects: 58
Study 30628950 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone continuous infusion (200 mg/d)
Number of subjects: 58
Study 28953070 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 352
Study 28953070 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace Dialogue Intervention (WDI)
Number of subjects: 352
Study 28953070 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT + WDI
Number of subjects: 352
Study 28953070 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 352
Study 25872578 — intervention group
Group type: EXPERIMENTAL
Intervention: PALO (0.75 mg, i.v.) and DEX (9.9 mg, i.v.) on day 1
Number of subjects: 305
Study 25872578 — intervention group
Group type: COMPARATOR
Intervention: PALO (0.75 mg, i.v.) and DEX (8 mg, i.v. or p.o.) on days 2-3
Number of subjects: 305
Study 25872578 — intervention group
Group type: EXPERIMENTAL
Intervention: PALO plus DEX day 1
Number of subjects: 305
Study 25872578 — intervention group
Group type: COMPARATOR
Intervention: PALO plus DEX days 1-3
Number of subjects: 305
Study 24959952 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg elemental iron daily supplements for 16 weeks
Number of subjects: 32
Study 24959952 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg elemental iron daily supplements for 16 weeks
Number of subjects: 32
Study 24959952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 22959886 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut diet (42.5 g of walnuts per 10.1 mJ 6 times per week)
Number of subjects: 25
Study 22959886 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish diet (113 g of fatty fish per 10.1 mJ 2 times per week)
Number of subjects: 25
Study 22959886 — intervention group
Group type: COMPARATOR
Intervention: Control diet (no nuts or fish)
Number of subjects: 25
Study 19754498 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention in a geriatric unit (GI) including educational measures and specific actions in seven risk areas (orientation, sensory impairment, sleep, mobilization, hydration, nutrition, drug use).
Number of subjects: 542
Study 19754498 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention in a geriatric unit (GI).
Number of subjects: 542
Study 19754498 — intervention group
Group type: COMPARATOR
Intervention: Usual care in two internal medicine services (UC).
Number of subjects: 542
Study 17446340 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel exhaust (particulate concentration, 300 microg/m(3))
Number of subjects: 15
Study 17446340 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 15
Study 15454616 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen
Number of subjects: 20
Study 15454616 — intervention group
Group type: COMPARATOR
Intervention: 30% oxygen
Number of subjects: 20
Study 11442156 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study 11442156 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (MDL)
Number of subjects: 20
Study 11442156 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (APACHE II score > or = 20)
Number of subjects: 20
Study 11442156 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (APACHE II score > or = 20)
Number of subjects: 20
Study 9756554 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 6 g daily for 3 days
Number of subjects: 14
Study 9756554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 9756554 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 14
Study 7836522 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI) using epididymal or testicular spermatozoa
Number of subjects: 0
Study 7836522 — intervention group
Group type: COMPARATOR
Intervention: Conventional in-vitro fertilization (IVF)
Number of subjects: 0
Study 7836522 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI/MESA
Number of subjects: 0
Study 7836522 — intervention group
Group type: COMPARATOR
Intervention: Conventional IVF
Number of subjects: 0
Study 3401660 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystoscopy plus urethral dilatation
Number of subjects: 100
Study 3401660 — intervention group
Group type: COMPARATOR
Intervention: Cystoscopy alone
Number of subjects: 100
Study 30942952 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 47
Study 30942952 — intervention group
Group type: COMPARATOR
Intervention: Control (UNCOVER-3)
Number of subjects: 47
Study 28688129 — intervention group
Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg, ruzasvir 60 mg, and uprifosbuvir 450 mg for 24 weeks
Number of subjects: 73